Methods for treating drug resistant cancer
AssigneeNovartis AG
InventorsGlenn C. Michelson, Vivien W. Chan, Carla C. Heise, Marion Wiesmann, Timothy D. Dawes
Life of this patent
Estimating the term…
Abstract
A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, wherein the patient is a cancer patient with drug-resistant cancer, wherein the compound of Formula I is as defined in the application.
Claims20
A method of treating drug-resistant cancer comprising administering to a drug-resistant cancer subject in need thereof, a compound of formula II, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, by inhibiting a cytoplasmic tyrosine kinase or a receptor tyrosine kinase comprising a mutant gatekeeper residue in the subject, wherein the kinase is ABL, KIT, PDGFRa, EGFR, or FLT3, and wherein the cancer is resistant to an anti-cancer drug selected from the group consisting of imatinib mesylate, BAY43-9006, Brostallicin, erlotinib, gefitinib, and vatalanib, and further wherein the compound of formula II has the following formula:
- wherein R7 is a substituted or unsubstituted heterocyclyl group selected from a substituted or unsubstituted piperidinyl group, piperazinyl group, or morpholinyl group.
A method of treating drug-resistant cancer comprising administering to a drug-resistant cancer subject in need thereof a compound, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, by inhibiting a cytoplasmic tyrosine kinase or a receptor tyrosine kinase comprising a mutant gatekeeper residue in the subject, wherein the kinase is ABL, KIT, PDGFRa, EGFR, or FLT3, and wherein the drug-resistant cancer is selected from the group consisting of prostate cancer, renal cancer, gastrointestinal stromal tumor, sarcoma, colorectal cancer, breast cancer, parotid cancer, gastric cancer, melanoma, oesophageal cancer, NET (sinonasal) cancer, colon cancer, ovarian cancer, liver cancer, acute myelogenous leukemia, chronic myelogenous leukemia, multiple myeloma, renal cell carcinoma, non-small cell lung cancer, and hypereosinophilic syndrome, and further wherein the compound has the following formula:
Dependencies are inferred from the claim text.